About Dr. Jin Zhou & SleepApneaUSA.net


Our Mission

SleepApneaUSA.net, founded by Dr. Jin Zhou, relied upon the latest research and clinically developed ZHT - Zhou's Hypoxicology Therapy to discover a possible cure for sleep apnea and provide an alternative care to those who can't tolerate CPAP,"sleeping mask".

Company Profile

SleepApneaUSA.net, founded by Dr. Jin Zhou, is a new business entity with clinically develop ZHT, and current offering teaching and clinical research on sleep apnea and sleep disordered breathing, chronic intermittent hypoxia related illness and diseases.

We have presently planned to explore further education of healthcare providers on sleep apnea, and our ZHT programs, and also the possiblities for ZHT to be integrading into current sleep care centers.

We also are planning to expand our ZHT clinical research, with other healthcare professionals participation, into many other major fatal medical conditions.

We are looking for visionary investors, strategic partners, business alliance and concerned healthcare providers to advance our goals, to find and provide with possible cure for sleep apnea, and its related major fatal medical conditions.

The Market — Sleep apnea, sleep-disordered breathing, and intermittent hypoxia have been identified and linked in latest research to almost all major fatal medical conditions, from heart attack, stroke, diabetes, COPD cancer, and major depressive disorders.

CPAP Merely Palliative in Obstructive Sleep Apnea Dec 2005 [Medscape (subscription)]

"NEW YORK (Reuters Health) Dec 21 - Treating obstructive sleep apnea (OSA) with nasal continuous positive airway pressure (CPAP) "is not a solution to the problem," researchers report in the December issue of the Annals of Neurology. The real problem is the underlying neurological lesions that cause disordered breathing and the solution, they say, is prevention of progression of OSA....

Summing up, he added that it is important to know the size and extent of the underlying neurological lesion before surgery. It is also "important to realize that nasal CPAP is not a complete solution and that non-compliance is a major problem... surgery may be a better solution."

Is obstructive sleep apnea syndrome a neurological disorder? A continuous positive airway pressure follow-up study.
Ann Neurol. 2005 Dec;58(6):880-7.
PMID: 16240364 [PubMed - in process]
Guilleminault C, Huang YS, Kirisoglu C, Chan A.

Obesity, High Blood Pressure Impacting Many U.S. Adults Ages 55-64 (Press Release- Dec 8, 2005) CDC Press

"Half of Americans aged 55-64 have high blood pressure – a major risk factor for heart disease and stroke – and two in five are obese, according to Health, United States, 2005, the government’s annual report to the President and Congress on the health of all Americans. The report was prepared by the Centers for Disease Control and Prevention’s (CDC) National Center for Health Statistics from data gathered by state and federal health agencies and through ongoing national surveys."

More couples sleeping in double beds, survey says
AZ Central.com, AZ - Dec 21, 2005

"Thus the blooming of sleep-study clinics.

According to the American Academy of Sleep Medicine, there are now more than 800 accredited centers in the United States."

Waking up to sleep problems - NorthJersey.com, NJ

"The search for deep, uninterrupted, refreshing sleep has become a national obsession. It's driving everything from the development of new prescription sleeping pills to extensive bed makeovers in hotel chains."

Sleep apnea is a serious, potentially life-threatening condition. It is a breathing disorder characterized by repeated collapse of the upper airway during sleep, with consequent cessation of breathing. Virtually all sleep apnea patients have a history of loud snoring. They may also unknowingly experience frequent arousals during the night, resulting in chronic daytime sleepiness or fatigue.

Sleep apnea appears to be as common as some better known diseases. It is estimated that 4 percent of middle-aged men and 2 percent of middle-aged women meet minimal criteria for sleep apnea syndrome.1 This compares to a 4.5 percent prevalence of asthma in middle-aged adults.2 Sleep apnea is more prevalent among the obese, in males, and in older individuals.3 There also seems to be a higher prevalence of sleep apnea in the hypertensive population.

As increasing in public awareness of sleep apnea and access and availability of sleep testing, the number of people suffering from sleep disordered breathing is growing faster than we can imagine, and it is estimated more than 50% of this population will fail in compliance of CPAP therapy or can't tolerate CPAP at all, thus the market and population for effective but alternative therapy is bigger than those under standard CPAP or surgical programs.

This market is one of the most explosive and largely untapped markets.
 

The Problem — Current main-stream treatment options are unsatisfactory, and the entire world is looking for a better or best solution.

As stated above, due to poor compliance of CPAP programs, a huge population of people with even known diagnosis of obstructive sleep apnea (OSA) or central sleep apnea (CSA) is left with no choices but suffering hopelessly.

ZHT- Zhou's Hypoxicolgy Therapy: Maximally establishing or opening Upper Airway (Vocal Cord, Entire Trachea), maximizing respiration through maximizing, optimizing and rematch in respiratory ventilation and perfusion through body’s own physiological functions - upper airway defense reflexes, such as swallowing and cough augmentation.

ZHT is an non-surgical, non-pharmaceutical and manual therapy that can be used to benefit most clinical conditions.

Unlike other therapies currently used for sleep apnea, ZHT (Zhou's hypoxicology Therapy) identifies the root causes of sleep apnea, employs human natural power, human systemic defense reflexes, volitional resuscitations to eliminate and relieve not only sleep apnea but also many other intermittent hypoxia related health problems.

Based currently published research and ZHT clinical observations, ZHT may have potential to provide therapeutic values for diabetes, cancers, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS) and many more sleep disordered breathing (SDB) and chronic intermittent hypoxia related major illness and diseases.